Toronto Institute of Pharmaceutical Technology’s Post

Uncover the nuances of deprescribing antihypertensive drugs for frail older adults. Balancing potential benefits and harms is key for optimal care. Learn more: https://bit.ly/3XuxXwZ Monash University Monash Pharmacy and Pharmaceutical Sciences University of Sydney University of South Australia Reeve Irvine Research Center (UCI) #AustralianPrescriber #healthcare #Deprescribing #AntihypertensiveDrugs

📢 The 🆕issue of Australian Prescriber reviews prescribing in three key areas: community-acquired #pneumonia, #hypertension and #Alzheimer disease. Discover the new articles and updates: https://bit.ly/3RFjURG #healthcare #QUM https://lnkd.in/eRYfp9kX

High costs keep one in 20 Canadians from being able to take their medications as prescribed, according to new research from UBC Faculty of Pharmaceutical Sciences. The findings highlight critical gaps in Canada’s healthcare system. In a nationally representative study of more than 223,000 Canadians ages 12 and older, researchers found that five per cent of respondents skipped doses, delayed refills or didn’t fill prescriptions at all due to out-of-pocket costs. Learn more about the study: https://bit.ly/4fOK2DB

🚨 Vertex’s New Cystic Fibrosis Drug: Hope or Hype? Vertex Pharmaceuticals just got FDA approval for Alyftrek, a breakthrough cystic fibrosis drug priced at a hefty $370,269/year. While it’s a game-changer for thousands, the steep cost has reignited debates on drug affordability. 💊 💡 Key Stats: 83,000+ CF patients in the U.S. $8.9B in revenue from Vertex’s CF portfolio last year. Is innovation worth the price? Let us know your thoughts! 🧬 Read more👇 https://lnkd.in/dwSy4ciA #Biotech #VertexPharma #CysticFibrosis #HealthcareInnovation #Health #Biotechnology #News

On #WorldOsteoporosisDay, let’s raise awareness about the importance of strong bones ; At Ampin's Pharma, we are committed to supporting innovative treatments through regulatory expertise, ensuring safe and effective therapies reach those in need. Osteoporosis is preventable and treatable. At Ampin’s Pharma, we play our part by guiding pharmaceutical innovations through complex regulations, ensuring access to life-changing therapies. This World Osteoporosis Day, Let’s prioritize bone health and make an impact, Let’s take a step toward healthier futures – together. Strong bones, Strong lives..!👍 If you like our posts, Be a connection with Ampin's Pharma and make sure to on notification of our profile to get informed for all our upcoming new posts.! #Ampin #Ampinspharma #AmpinsDrugRegulatoryServices #draconsultant #Drugregulatoryconsultant #dra #pharmacies #sucess #pharmalife #goals #picoftheday #health #regulatoryexcellence #goodhealth #regulatoryoutsource #draconsultant #pharmacist #Drugregulatoryconsultant #osteoporasis #medicalpost #regulatoryaffairs #healthybones

As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience. Read more here: https://lnkd.in/ecKcTr7J #pharma #biosimilars #us #healthcare #news

Public Notice: Important Update on Pilocarpine Hydrochloride Ophthalmic Solution USP 1.25% w/v As per File No. SND/MA/22/000301, the Directorate General of Health Services, Central Drugs Standard Control Organization (CDSCO), has issued a notification regarding misleading claims made about Pilocarpine Hydrochloride Ophthalmic Solution USP 1.25% w/v. Please note: - This product is only approved for the treatment of Presbyopia in adults. - Claims that it can reduce the need for reading glasses or enhance near vision within 15 minutes are unapproved and misleading. Stay cautious and rely on accurate, approved information for your healthcare needs. || Indian Pharmaceutical Association || #PublicNotice #HealthAwareness #CDSCO #EyeHealth #PilocarpineHydrochloride #PresbyopiaTreatment #StayInformed #HealthcareUpdates #ConsumerSafety #DrugSafety

Phase II of the "Chemist Insulin Education Programme," organized by USV in collaboration with IPA's Community Pharmacy Division and Bluetree Healthcare Solutions, focused on "Good Insulin Storage Practices." 📄💊 This multilingual webinar series, conducted in September 2024, reached over 1,535 pharmacists across India. Learn more about it in the 59th issue of the IPA-CPD E-times ✨ Read more here: https://bit.ly/3AL3bHi Indian Pharmaceutical Association || Manjiri Gharat || Raj Vaidya #IPA #IPA_CPD #59thEtimes #PharmacistEducation #InsulinStorage #CommunityPharmacy #DiabetesCare #MultilingualLearning

I am pleased to have participated in the 7th National Pharmaceutical Conference, held on April 12-13. During the conference, I presented three key topics crucial to the health environment. 1. “Social Pharmacy, Role, and Importance in Healthcare”: In this presentation, we thoroughly examined the role and impact of social pharmacy in healthcare. We discussed strategies to improve patient access to medications and promote a more holistic and personalized care approach. 2. “Drug Interactions in Diabetic Patients”: Another topic we addressed was drug interactions in diabetic patients, emphasizing the importance of careful and personalized management of their therapy to minimize risks and optimize health outcomes. 3. “Evaluation of Drug Prescription Models Based on World Health Organization Indicators”: Finally, we analyzed current drug prescription models, focusing on WHO indicators. We discussed the advantages and challenges of these models and identified opportunities for improvement. This conference served as an important platform for knowledge exchange and influencing the development of the pharmaceutical field to ensure better healthcare for all. #Pharmacy #Healthcare #PharmaceuticalConference7 #Albania

Essential Medicines Session (Session #4) at the 2025 Canadian Society for Pharmaceutical Sciences Symposium in Montreal, QC, Canada on May 28th sponsored by NGDI UBC. More Details Shortly: https://lnkd.in/gTFScDvc #beatntds #essentialmedicines #equity #affordability #access #healthcare